Ventana Biotech, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VNTA research report →
Price Chart
About the company
Ventana Biotech, Inc. is an emerging biotechnology enterprise focused on the lifecycle of drug candidates for personalized medicine, encompassing the identification, assessment, acquisition, development, and eventual commercialization through partnerships of relevant intellectual property. The company's primary therapeutic area is addressing obesity and its associated medical conditions.
- CEO
- Stephen Replin
- IPO
- 2009
- Employees
- 1
- HQ
- Denver, CO, US
Get TickerSpark's AI analysis on VNTA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $159.69K
- P/E
- 36.25
- PEG
- 0.12
- P/S
- 1.39
- P/B
- 0.00
- EV/EBITDA
- 1.58
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 87.99%
- Net Margin
- 75.18%
- ROE
- 0.00%
- ROIC
- 0.00%
Latest fiscal year · YoY change
- Revenue
- $114.58K+177.0%
- Gross Profit
- $0+0.0%
- Op Income
- $100.81K
- Net Income
- $86.14K+333.1%
- EPS
- $0.00+300.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $0.08
- 52W Low
- $0.03
- 50D MA
- $0.04
- 200D MA
- $0.04
- Beta
- -3.53
- RSI (14)
- 66
- Avg Volume
- 732
No earnings-call transcripts are available for VNTA yet.
- Free Float
- 0.0%
- Shares Outstanding
- 2.75M
- Float Shares
- 0
Our VNTA coverage
Recent articles, reports, and earnings notes.
No research on VNTA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VNTA report →Vanta Attends 2026 All-In Summit in Los Angeles, a Leading Gathering of Business, Investment and Industry Leaders
accessnewswire.com · Sep 17
Vanta Announces Engagement of Independent Trading Group for Market-Making Services to Support Strategic Capital Markets Initiatives
accessnewswire.com · Aug 27
Vanta Announces Updated Time for Participation in the "Health, Wellness & Longevity" Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22, 2026, at 12:00 p.m. ET
accessnewswire.com · Jul 21
Vanta Announces Closing of Second Tranche of Private Placement for Aggregate Gross Proceeds of $1 Million
accessnewswire.com · May 6
Vanta Announces Closing of First Tranche of Private Placement and Debt Settlement
accessnewswire.com · May 5
Ventana Global, Inc. (VNTA) Reports Fiscal Year 2025 Results and Publishes Annual Report; Discloses Initial Lending Activity
feeds.newsfilecorp.com · Mar 27
Ventana Biotech, Inc. (VNTAD) Announces Name Change to Ventana Global, Inc. and Significant Outstanding Share Reduction
newsfilecorp.com · Jan 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.